Every year, thousands of cancer patients on immunotherapy hit a wall: their tumors develop resistance, their treatments stop working, and clinicians face no validated alternatives. Today, HITLAB and ENB Therapeutics announce a partnership designed to change that trajectory. Together, they are converting ENB's groundbreaking small-molecule therapies--engineered to restore immunotherapy effectiveness--into the clinical and commercial evidence that investment partners and pharmaceutical giants' demand.
